This is the authors' abstract. We don't add key points for this paper.
In recent years, precision oncology has transformed cancer care, especially in high-income settings. From detection to personalized treatment strategies, biospecimens obtained from patients are analyzed using next-generation techniques and patients are matched to targeted therapies, which have proven to improve cancer survival rates.1However, most parts of Africa remain largely bystanders to this revolution, mainly because of the inadequate infrastructure, underrepresented data, and insufficient funding architecture that make cancer precision medicine possible.
No takes yet. Share an insight, caveat, or question.
Omoruyi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: